Clinical Trial Update: Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

Terminated Phase 2/3 trial evaluating darbepoetin alfa (Aranesp) for anemia in patients with advanced hormone-independent prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Prostate Cancer

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: University of Aarhus | Conditions: Prostatic Neoplasms, Anemia | Phase 2, Phase 3 | Status: TERMINATED